Exhibit 1
Top Alliances In January 2015
Deals In Depth: January 2015
In a deal worth over $1 billion, Depomed got US rights to Janssen's pain drug Nucynta; Roche bought the majority stake in Foundation Medicine. FOPOs drove a large part of biopharma financing.
More from Deal-Making
More from In Vivo
• By
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
• By
Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.
• By
A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.